GlobalData Plc
  • Press Release

    Number of Immuno-Oncology (IO) trials in China surge by more than 50% in 2016 and 2017, finds GlobalData

In recent years, China increased its focus on the clinical trial investigation of immuno-oncology (I/O) drug candidates. The number of clinical trials recorded a compound annual growth rate (CAGR) of ~34% since 2008, according to leading data and analytics company GlobalData.

GlobalData identified 819 clinical trials that have been initiated in the last 10 years (2008-17) to investigate I/O drug candidates. More than half (n=464) of these trials were initiated in 2016 and 2017.

Phase II clinical trials accounted for nearly 28% of the total clinical trials conducted in China, followed by Phase I (24%) and Phase I/II (24%).

In the I/O clinical trials, 67% of the trials were in progress, 24% were completed and 5% were planned. Out of these completed trials, 51% were reported with results.

FUDA Cancer Hospital is the major non-industry player investigating I/O drug candidates in China. The other top non-industry sponsors were China PLA General Hospital, Sun Yat-sen University.

Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd emerged as the top industry sponsor. Other top industry sponsors were Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd and Novartis AG.

The major indications under investigation include Non-Small Cell Lung Cancer, Solid Tumor, Hepatocellular Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), and Breast Cancer, etc.

The top five I/O drug candidates investigated in the clinical trials that were started in recent years (2016-17) include Cellular Immunotherapy for Oncology, tucidinostat, SHR-1210, nivolumab and anlotinib hydrochloride. 

ENDS

Analysts available for comment. Please contact the GlobalData Press Office at pr@globaldata.com.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF